CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.5B, above the global median of $1.15B
- FinancialsAltman Z-Score 0.77: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.50BUSDvs all stocks (USD)
Revenue (TTM)
1.64BUSDvs all stocks (USD)
Profit Margin
-30.15%vs Medical Devices peers
Beta
1.22xvs all stocks
52-Week Change
69.31%vs all stocks
Market Capitalization
1.50BUSDvs all stocks (USD)
Enterprise Value
3.24BUSDvs all stocks (USD)
Forward P/E
7.58xvs Medical Devices peers
Price to Sales (TTM)
0.9390xvs Medical Devices peers
Price to Book (MRQ)
1.48xvs Medical Devices peers
Enterprise to Revenue
1.97xvs Medical Devices peers
Enterprise to EBITDA
10.50xvs Medical Devices peers
Gross Margin
55.36%vs Medical Devices peers
Profit Margin
-30.15%vs Medical Devices peers
Operating Margin
10.41%vs Medical Devices peers
Return on Assets (TTM)
2.54%vs Medical Devices peers
Return on Equity (TTM)
-38.63%vs Medical Devices peers
Revenue (TTM)
1.64BUSDvs all stocks (USD)
Revenue per Share (TTM)
21.41USDUpdated Jul 19, 2026Quarterly Revenue Growth
2.40%vs Medical Devices peers
Gross Profit (TTM)
932.69MUSDvs all stocks (USD)
EBITDA (TTM)
218.47MUSDvs all stocks (USD)
Net Income (TTM)
-495.80MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
2.42%vs Medical Devices peers
Operating Cash Flow (TTM)
71.44MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
69.29MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.64BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
803.63MUSDFY2025 · Dec 31, 2025Gross Profit
831.62MUSDFY2025 · Dec 31, 2025Operating Income
18.00MUSDvs all stocks (USD)
Pre-tax Income
-563.50MUSDFY2025 · Dec 31, 2025Income Tax Expense
-47.03MUSDFY2025 · Dec 31, 2025Net Income
-516.47MUSDFY2025 · Dec 31, 2025EBIT
-477.25MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
185.95MUSDFY2025 · Dec 31, 2025Research & Development
98.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
699.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
18.47MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
86.25MUSDFY2025 · Dec 31, 2025EPS (Basic)
-6.74USDFY2025 · Dec 31, 2025EPS (Diluted)
-6.74USDFY2025 · Dec 31, 2025Basic Shares Outstanding
76.67MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
76.67MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-516.47MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-458.67MUSDFY2025 · Dec 31, 2025Free Cash Flow
-540.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
235.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-516.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
151.83MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-66.26MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.58MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-15.41MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-485.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
26.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-57.17MUSDFY2025 · Dec 31, 2025Capital Expenditures
-81.44MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-14.20MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-19.43MUSDFY2025 · Dec 31, 2025Sale of Investments
7.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-93.86MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
720.70MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-669.89MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-221.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-23.21MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
27.38MUSDFY2025 · Dec 31, 2025Shares Outstanding
77.82MSharesUpdated Jul 19, 2026Float Shares
58.70MSharesUpdated Jul 19, 2026Shares Short
6.39MSharesUpdated Jul 19, 2026Short Ratio
6.52daysvs all stocks
Short % of Shares Outstanding
11.33%vs all stocks
% Held by Insiders
14.29%vs all stocks
% Held by Institutions
100.18%vs all stocks
Total Cash (MRQ)
265.50MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.41USDUpdated Jul 19, 2026Total Debt (MRQ)
2.04BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.96xvs Medical Devices peers
Current Ratio (MRQ)
3.38xvs Medical Devices peers
Book Value per Share (MRQ)
13.39USDUpdated Jul 19, 2026Total Assets
3.60BUSDvs all stocks (USD)
Total Current Assets
1.16BUSDFY2025 · Dec 31, 2025Total Liabilities
2.56BUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.44BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.10BUSDFY2025 · Dec 31, 2025Total Current Liabilities
455.98MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
235.05MUSDFY2025 · Dec 31, 2025Other Short-term Investments
28.69MUSDFY2025 · Dec 31, 2025Accounts Receivable
278.85MUSDFY2025 · Dec 31, 2025Inventory
492.74MUSDFY2025 · Dec 31, 2025Accounts Payable
95.73MUSDFY2025 · Dec 31, 2025Short-term Debt
140.57MUSDFY2025 · Dec 31, 2025Deferred Revenue
11.46MUSDFY2025 · Dec 31, 2025Long-term Debt
1.89BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
204.28MUSDFY2025 · Dec 31, 2025Common Stock (Book)
923.00KUSDFY2025 · Dec 31, 2025Retained Earnings
423.44MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.04BUSDvs all stocks (USD)
Treasury Stock
689.21MUSDFY2025 · Dec 31, 202552-Week Low
8.70USDUpdated Jul 19, 202652-Week High
20.26USDUpdated Jul 19, 202652-Week Change
69.31%vs all stocks
Beta
1.22xvs all stocks
50-Day MA
16.42USDUpdated Jul 19, 2026200-Day MA
13.05USDUpdated Jul 19, 2026Avg 10-Day Volume
832.77KSharesUpdated Jul 19, 2026Avg 30-Day Volume
926.58KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-6.47USDUpdated Jul 19, 2026Other Income / Expense
-513.72MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.55Profit Margin: -0.30
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.38Altman Z-Score: 0.77
Financial Health
Altman Z-Score 0.77: distress zoneCritical
Altman Z-Score: 0.77
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.5B, above the global median of $1.15BNotable
Market cap (USD): 1,497,590,382Global Median: 1,146,734,693.424
Revenue is $1.64B, above the global median of $520.53MNotable
Revenue (USD): 1,644,509,952Global Median: 520,528,949.311
Levered free cash flow is $69.29M, above the global median of $16.24MNotable
Levered free cash flow (USD): 69,289,752Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
China Traditional Chinese Medicine Holdings Co. Limited
Tier 1ProductionApproval-Gated PipelineFlowInterface
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Dauch Corporation
1 interpretationWithin or Near the Altman Distress Zone
Datang Telecom Technology Co. Ltd.
1 interpretationWithin or Near the Altman Distress Zone
Kosmos Energy Ltd.
1 interpretationWithin or Near the Altman Distress Zone